Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for PRASUGREL HYDROCHLORIDE
- Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention
- De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS
- Prasugrel Or Ticagrelor De-escalation in NSTE-ACS
- Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy
- PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
- Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
- Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study
- Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)
- Polypill in Acute Coronary Syndrome
- Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
- Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent
- Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured Aneurysm
- Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel
- Clopidogrel Monotherapy in Patients With High Bleeding Risk
- Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
- Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study
- CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4
- Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease
- Mono Antiplatelet and Colchicine Therapy
- Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy
- Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
- Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)
- Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
- Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
- VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
- Prasugrel in Severe COVID-19 Pneumonia
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
- The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
- Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion
- The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
- Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
- Ticagrelol Versus Aspirin in Ischemic Stroke
- Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
- Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
- Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
- SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance to Examine the Safety of Cessation of Dual Anti-Platelet Therapy in High Bleeding Risk Patients at One Month
- Trimetazidine as an Adjunct to Enhance Clopidogrel Response.
- Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm
- Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
- Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease
- Acetyl Salicylic Elimination Trial: The ASET Pilot Study
- Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor
- Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI
- A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
- Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction
- CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI
- Add-on Cangrelor in STEMI-triggered Cardiac Arrest
- Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
- Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI
- Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study
- Study of AggreGuide A-100 (ADP) Assay
- Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients
- A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response
- Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study
- Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets
- A Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During TAVI
- Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
- Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
- Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI
- Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
- Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients
- Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
- Polypectomy in Patients Taking Dual Antiplatelet Agents
- Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents
- Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction
- WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
- The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation
- Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting
- Ticagrelor in Human Endotoxemia Response to Human Endotoxemia
- EVOLVE Short DAPT Study
- Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
- Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)
- Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention
- Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
- ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts
- Ticagrelor vs. Prasugrel Effects on Infarct Size
- Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting
- Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI
- Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
- Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling
- Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor
- P3AMI Antiplatelet Trial
- Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly
- Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART
- Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients
- Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
- High "on Treatment" Platelet Reactivity in the Intensive Care Unit
- Ticagrelor and Endothelial Function
- Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.
- Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate
- Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis
- Pharmacological Effects of Crushing Prasugrel in STEMI Patients
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)
- REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
- Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent
- Effect of Ticagrelor on Fractional Flow Reserve
- Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)
- In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
- Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers
- Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction
- Prasugrel With Lower Dose - Loading Dose
- A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
- Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy
- Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .
- Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa)
- "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
- Cangrelor to Clopidogrel or Prasugrel Transition Study
- Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.
- Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial
- Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease
- OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
- Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome
- Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
- PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males
- Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
- Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes
- Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
- Cangrelor Prasugrel Transition Study
- High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
- A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
- Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
- Rapid Activity of Platelet Inhibitor Drugs Study 2
- A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
- BLeeding Events and Maintenance DoSe of PraSugrel
- Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
- Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome
- The Elderly ACS II Trial
- Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome
- Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke
- Platelet Inhibition in Patients With Systolic Heart Failure
- Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study
- VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
- A Study of Prasugrel in Healthy Participants
- Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
- Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study
- PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
- Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome
- Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
- Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention
- The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency
- Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
- ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography
- Study of Prasugrel in Korean Healthy Male Volunteers
- PROMUS Element Plus US Post-Approval Study
- Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
- Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
- High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
- Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel
- The Effect of Morphine on Prasugrel Absorption in STEMI Patients
- PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus
- How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
- Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
- Effect of Proton Pump Inhibitor on Residual Platelet Reactivity After Clopidogrel in Homogenous Genetic Strata
- PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)
- Rapid Activity of Platelet Inhibitor Drugs Study
- Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
- The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)
- Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity
- A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
- Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial
- Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
- Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
- Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing
- Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
- Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
- A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
- Drug Drug Interactions of Aspirin and P2Y12-inhibitors
- The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel
- Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention
- Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy Volunteers
- Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention
- Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)
- Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse
- Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI
- The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma
- Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment
- Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
- The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
- Prasugrel Re-load Strategies
- An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
- Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.
- Prasugrel Versus Placebo in Adult Sickle Cell Disease
- Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI
- Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
- Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
- Pocket Haematoma Prevention in Patients Who Required Implantation/Replacement of a Pacemaker or Implantable Cardiac Defibrillator. The PHP Study.
- Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
- Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
- Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).
- Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
- Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
- Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
- Plavix, Prasugrel and Drug Eluting Stents Pilot Trial
- Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
- The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation
- Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome
- European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
- EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
- A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
- Prasugrel/Clopidogrel Maintenance Dose Washout Study
- Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism
- TAXUS Libertē Post Approval Study
- Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction
- Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time
- Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism
- Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
- Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism
- A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
- Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy
- The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
- A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
- Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
- The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
- Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
- Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event
- A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
- A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Clinical trials list
click for details